I am working with a drug which causes inflammation via Nfkb (p65) phosphorylation and the phosphorylation occur through IKK activation. But the co-treated of this drug with BAY 11 7082 ( inhibitor of the NF-kB signaling cascade ) does not down-regulated Nfkb phosphorylation however its downstream proteins (eg: COX-2) are decreased significantly. In addition BAY 117082 alone treatment causes Nfkb phosphorylation. Does any one can explain why I am getting this kind of results. I treat drug in MDA MB 231 cell line (Metastatic breast cancer cells) and using whole cell lysate for western blotting.
I had a similar response and so I used another drug Sulfasalazine. It worked nicely Article Suppression of NF-kappaB activity by sulfasalazine is mediat...
Thank you Zahid Pranjol and Jörn Holger Buchbinder, I really appreciate your suggestion. I will try soon.
I had same issue with Proteosome Inhibitors (eg: Bortizomib and MG 132).
- Badges
- Science topic